User login
CHICAGO – Publicly funded research in oncology has great potential for reducing the costs of health care. Over the last 10 years, however, funding has dropped off appreciably.
In an exclusive interview at the annual meeting of the American Society of Clinical Oncology, Dr. Monica M. Bertagnolli, group chair of the Alliance for Clinical Trials in Oncology, discusses how cost-saving advances in oncology are being affected by the cut backs.
CHICAGO – Publicly funded research in oncology has great potential for reducing the costs of health care. Over the last 10 years, however, funding has dropped off appreciably.
In an exclusive interview at the annual meeting of the American Society of Clinical Oncology, Dr. Monica M. Bertagnolli, group chair of the Alliance for Clinical Trials in Oncology, discusses how cost-saving advances in oncology are being affected by the cut backs.
CHICAGO – Publicly funded research in oncology has great potential for reducing the costs of health care. Over the last 10 years, however, funding has dropped off appreciably.
In an exclusive interview at the annual meeting of the American Society of Clinical Oncology, Dr. Monica M. Bertagnolli, group chair of the Alliance for Clinical Trials in Oncology, discusses how cost-saving advances in oncology are being affected by the cut backs.
AT THE ASCO ANNUAL MEETING 2013